Antibiotic-induced collateral damage to the microbiota and associated infections

1. Browne, A. J. et al. Global antibiotic consumption and usage in humans, 2000–18: a spatial modelling study. Lancet Planet. Health 5, e893–e904 (2021).

   PubMed 
   PubMed Central 

   Google Scholar 

2. Stewardson, A. J., Huttner, B. & Harbarth, S. At least it won’t hurt: the personal risks of antibiotic exposure. Curr. Opin. Pharmacol. 11, 446–452 (2011).

   CAS 
   PubMed 

   Google Scholar 

3. Blaser, M. J. Antibiotic use and its consequences for the normal microbiome. Science 352, 544–545 (2016).

   CAS 
   PubMed 
   PubMed Central 

   Google Scholar 

4. Hogenauer, C., Hammer, H. F., Krejs, G. J. & Reisinger, E. C. Mechanisms and management of antibiotic‐associated diarrhea. Clin. Infect. Dis. 27, 702–710 (1998).

   CAS 
   PubMed 

   Google Scholar 

5. McFarland, L. V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig. Dis. Basel Switz. 16, 292–307 (1998).

   CAS 

   Google Scholar 

6. Caballero-Flores, G., Pickard, J. M. & Núñez, G. Microbiota-mediated colonization resistance: mechanisms and regulation. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-022-00833-7 (2022). A comprehensive review on the mechanisms and regulation of colonization resistance.

   Article 
   PubMed 

   Google Scholar 

7. Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016).

   PubMed 
   PubMed Central 

   Google Scholar 

8. Faith, J. J. et al. The long-term stability of the human gut microbiota. Science 341, 1237439 (2013).

   PubMed 
   PubMed Central 

   Google Scholar 

9. Wypych, T. P. & Marsland, B. J. Antibiotics as instigators of microbial dysbiosis: implications for asthma and allergy. Trends Immunol. 39, 697–711 (2018).

   CAS 
   PubMed 

   Google Scholar 

10. Yuan, J. et al. Long-term use of antibiotics and risk of type 2 diabetes in women: a prospective cohort study. Int. J. Epidemiol. 49, 1572–1581 (2020).

    PubMed 
    PubMed Central 

    Google Scholar 

11. Park, S. J. et al. Association between antibiotics use and diabetes incidence in a nationally representative retrospective cohort among Koreans. Sci. Rep. 11, 21681 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

12. Zhou, W. et al. Longitudinal multi-omics of host–microbe dynamics in prediabetes. Nature 569, 663–671 (2019).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

13. Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369–2379 (2016).

    CAS 
    PubMed 

    Google Scholar 

14. Trasande, L. et al. Infant antibiotic exposures and early-life body mass. Int. J. Obes. 37, 16–23 (2013).

    CAS 

    Google Scholar 

15. Teng, C., Reveles, K. R., Obodozie-Ofoegbu, O. O. & Frei, C. R. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system. Int. J. Med. Sci. 16, 630–635 (2019).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

16. Högenauer, C. et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N. Engl. J. Med. 355, 2418–2426 (2006).

    PubMed 

    Google Scholar 

17. Shukla, A. & Sobel, J. D. Vulvovaginitis caused by Candida species following antibiotic exposure. Curr. Infect. Dis. Rep. 21, 44 (2019).

    PubMed 

    Google Scholar 

18. Ben-Ami, R. et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob. Agents Chemother. 56, 2518–2523 (2012).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

19. Ichinohe, T. et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl Acad. Sci. USA 108, 5354–5359 (2011).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

20. Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. V. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42–51 (2014).

    PubMed 

    Google Scholar 

21. Bush, K. et al. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9, 894–896 (2011).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

22. Yassour, M. et al. Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci. Transl. Med. 8, 343ra81 (2016). This longitudinal study of the infant gut microbiome observed transient blooms of specific species and resistance levels during antibiotic treatment.

    PubMed 
    PubMed Central 

    Google Scholar 

23. Stecher, B., Maier, L. & Hardt, W.-D. ‘Blooming’ in the gut: how dysbiosis might contribute to pathogen evolution. Nat. Rev. Microbiol. 11, 277–284 (2013).

    CAS 
    PubMed 

    Google Scholar 

24. Buffie, C. G. et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 80, 62–73 (2012).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

25. Shen, Z. et al. Emerging carriage of NDM-5 and MCR-1 in Escherichia coli from healthy people in multiple regions in China: a cross sectional observational study. eClinicalMedicine 6, 11–20 (2018).

    PubMed 
    PubMed Central 

    Google Scholar 

26. van Hattem, J. M. et al. Prolonged carriage and potential onward transmission of carbapenemase-producing Enterobacteriaceae in Dutch travelers. Future Microbiol. 11, 857–864 (2016).

    PubMed 

    Google Scholar 

27. Hu, Y. et al. Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. Nat. Commun. 4, 2151 (2013).

    PubMed 

    Google Scholar 

28. Group, B. M. J. P. Superinfections during antibiotic treatment. Br. Med. J. 1, 537–538 (1952).

    Google Scholar 

29. Ramirez, J. et al. Antibiotics as major disruptors of gut microbiota. Front. Cell. Infect. Microbiol. 10, 572912 (2020).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

30. Sullivan, Å. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 1, 101–114 (2001). A review of the drug-specific effects of antibiotic on the microbiota, including extra-intestinal microbiota sites.

    CAS 
    PubMed 

    Google Scholar 

31. Yang, L. et al. The varying effects of antibiotics on gut microbiota. AMB Express 11, 116 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

32. Maier, L. et al. Unravelling the collateral damage of antibiotics on gut bacteria. Nature 599, 120–124 (2021). This study comprehensively screened gut commensals to identify drug combinations active against pathogens but that minimize collateral damage against other species.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

33. Kelly, S. A., Rodgers, A. M., O’Brien, S. C., Donnelly, R. F. & Gilmore, B. F. Gut check time: antibiotic delivery strategies to reduce antimicrobial resistance. Trends Biotechnol. 38, 447–462 (2020).

    CAS 
    PubMed 

    Google Scholar 

34. Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108, 4554–4561 (2011). This study highlights the differences between individuals in the microbiota response and recovery to antibiotics.

    CAS 
    PubMed 

    Google Scholar 

35. Jeffery, I. B., Lynch, D. B. & O’Toole, P. W. Composition and temporal stability of the gut microbiota in older persons. ISME J. 10, 170–182 (2016).

    CAS 
    PubMed 

    Google Scholar 

36. Zimmermann, M., Patil, K. R., Typas, A. & Maier, L. Towards a mechanistic understanding of reciprocal drug–microbiome interactions. Mol. Syst. Biol. 17, e10116 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

37. Gjonbalaj, M. et al. Antibiotic degradation by commensal microbes shields pathogens. Infect. Immun. 88, e00012–e00020 (2020).

    PubMed 
    PubMed Central 

    Google Scholar 

38. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

39. Byrd, A. L., Belkaid, Y. & Segre, J. A. The human skin microbiome. Nat. Rev. Microbiol. 16, 143–155 (2018).

    CAS 
    PubMed 

    Google Scholar 

40. Elvers, K. T. et al. Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review. BMJ Open 10, e035677 (2020).

    PubMed 
    PubMed Central 

    Google Scholar 

41. Zimmermann, P. & Curtis, N. The effect of antibiotics on the composition of the intestinal microbiota — a systematic review. J. Infect. 79, 471–489 (2019).

    PubMed 

    Google Scholar 

42. Levison, M. E. & Levison, J. H. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect. Dis. Clin. North. Am. 23, 791–815 (2009).

    PubMed 
    PubMed Central 

    Google Scholar 

43. Levy, R. M., Huang, E. Y., Roling, D., Leyden, J. J. & Margolis, D. J. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch. Dermatol. 139, 467–471 (2003).

    CAS 
    PubMed 

    Google Scholar 

44. Kim, S., Covington, A. & Pamer, E. G. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol. Rev. 279, 90–105 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

45. Kelly, S. A. et al. Antibiotic therapy and the gut microbiome: investigating the effect of delivery route on gut pathogens. ACS Infect. Dis. 7, 1283–1296 (2021).

    CAS 
    PubMed 

    Google Scholar 

46. Zhang, L., Huang, Y., Zhou, Y., Buckley, T. & Wang, H. H. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. Antimicrob. Agents Chemother. 57, 3659–3666 (2013). A comparison of oral and intravenous antibiotic administration on the spread of antibiotic resistance in the mouse intestine.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

47. Finegold, S. M. Anaerobic infections in humans: an overview. Anaerobe 1, 3–9 (1995).

    CAS 
    PubMed 

    Google Scholar 

48. Eckburg, P. B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635–1638 (2005).

    PubMed 
    PubMed Central 

    Google Scholar 

49. Donskey, C. J. et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343, 1925–1932 (2000). This study of patients colonized with vancomycin-resistant enterococci showed overgrowth in the intestine during treatment with various anti-anaerobic antibiotics.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

50. Brook, I., Wexler, H. M. & Goldstein, E. J. C. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin. Microbiol. Rev. 26, 526–546 (2013).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

51. Taur, Y. et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 55, 905–914 (2012). Intestinal domination by various bacteria is associated with subsequent bacteraemia in patients undergoing haematopoietic stem cell transplantation.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

52. Young, V. B. & Schmidt, T. M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J. Clin. Microbiol. 42, 1203–1206 (2004).

    PubMed 
    PubMed Central 

    Google Scholar 

53. Wiström, J. et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J. Antimicrob. Chemother. 47, 43–50 (2001).

    PubMed 

    Google Scholar 

54. Ma, H. et al. Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients. Infect. Drug. Resist. 12, 1047–1054 (2019).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

55. Rashidi, A. et al. Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. Microbiome 9, 211 (2021).

    PubMed 
    PubMed Central 

    Google Scholar 

56. Arvidsson, A., Leijd, B., Nord, C. E. & Angelin, B. Interindividual variability in biliary excretion of ceftriaxone: effects on biliary lipid metabolism and on intestinal microflora. Eur. J. Clin. Invest. 18, 261–266 (1988).

    CAS 
    PubMed 

    Google Scholar 

57. Coyte, K. Z., Schluter, J. & Foster, K. R. The ecology of the microbiome: networks, competition, and stability. Science 350, 663–666 (2015).

    CAS 
    PubMed 

    Google Scholar 

58. Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).

    PubMed 
    PubMed Central 

    Google Scholar 

59. Anthony, W. E. et al. Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults. Cell Rep. 39, 110649 (2022). This study shows short- and long-term effects of antibiotics on the gut microbiota of healthy volunteers.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

60. Yee, A. L. et al. Longitudinal microbiome composition and stability correlate with increased weight and length of very-low-birth-weight infants. mSystems 4, e00229-18 (2019).

    PubMed 
    PubMed Central 

    Google Scholar 

61. Sorg, R. A. et al. Collective resistance in microbial communities by intracellular antibiotic deactivation. PLoS Biol. 14, e2000631 (2016).

    PubMed 
    PubMed Central 

    Google Scholar 

62. Cubillos-Ruiz, A. et al. An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis. Nat. Biomed. Eng. 6, 910–921 (2022).

    CAS 
    PubMed 

    Google Scholar 

63. Sun, J. et al. Environmental remodeling of human gut microbiota and antibiotic resistome in livestock farms. Nat. Commun. 11, 1427 (2020).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

64. Foster, K. R., Schluter, J., Coyte, K. Z. & Rakoff-Nahoum, S. The evolution of the host microbiome as an ecosystem on a leash. Nature 548, 43–51 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

65. Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1125–1136.e8 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

66. Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

67. Montandon, S. A. & Jornayvaz, F. R. Effects of antidiabetic drugs on gut microbiota composition. Genes 8, 250 (2017).

    PubMed 
    PubMed Central 

    Google Scholar 

68. Le Bastard, Q. et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment. Pharmacol. Ther. 47, 332–345 (2018).

    PubMed 

    Google Scholar 

69. Kwok, C. S. et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 107, 1011–1019 (2012).

    CAS 
    PubMed 

    Google Scholar 

70. Trifan, A. et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J. Gastroenterol. 23, 6500–6515 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

71. Caballero-Flores, G., Pickard, J. M., Fukuda, S., Inohara, N. & Núñez, G. An enteric pathogen subverts colonization resistance by evading competition for amino acids in the gut. Cell Host Microbe 28, 526–533.e5 (2020).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

72. Theriot, C. M. et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 5, 3114 (2014).

    PubMed 

    Google Scholar 

73. Sassone-Corsi, M. et al. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature 540, 280–283 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

74. Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13, 790–801 (2013).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

75. Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337–349 (2008).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

76. Deshmukh, H. S. et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat. Med. 20, 524–530 (2014).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

77. Pamer, E. G. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352, 535–538 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

78. Freter, R. The fatal enteric cholera infection in the guinea pig, achieved by inhibition of normal enteric flora. J. Infect. Dis. 97, 57–65 (1955). An early study identifying the protection against infection conferred by an intact microbiota.

    CAS 
    PubMed 

    Google Scholar 

79. Miller, C. P., Bohnhoff, M. & Rifkind, D. The effect of an antibiotic on the susceptibility of the mouse’s intestinal tract to Salmonella infection. Trans. Am. Clin. Climatol. Assoc. 68, 51–58 (1957).

    CAS 
    PubMed Central 

    Google Scholar 

80. Sekirov, I. et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect. Immun. 76, 4726–4736 (2008).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

81. Hensgens, M. P. M., Goorhuis, A., Dekkers, O. M. & Kuijper, E. J. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J. Antimicrob. Chemother. 67, 742–748 (2012). A multicenter case–control study to determine the period at risk for CDI after cessation of antibiotics.

    CAS 
    PubMed 

    Google Scholar 

82. Tvede, M. & Rask-Madsen, J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 333, 1156–1160 (1989).

    Google Scholar 

83. van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).

    PubMed 

    Google Scholar 

84. Buffie, C. G. et al. Precision microbiome restoration of bile acid-mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015). Bile-acid-mediated colonization resistance against C. difficile could be restored by the human gut commensal C. scindens.

    CAS 
    PubMed 

    Google Scholar 

85. Aguirre, A. M. et al. Bile acid-independent protection against Clostridioides difficile infection. PLoS Pathog. 17, e1010015 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

86. Gregory, A. L., Pensinger, D. A. & Hryckowian, A. J. A short chain fatty acid-centric view of Clostridioides difficile pathogenesis. PLoS Pathog. 17, e1009959 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

87. Iwata, K. et al. A systematic review for pursuing the presence of antibiotic associated enterocolitis caused by methicillin resistant Staphylococcus aureus. BMC Infect. Dis. 14, 247 (2014).

    PubMed 
    PubMed Central 

    Google Scholar 

88. Lane, A. B., Copeland, N. K., Onmus-Leone, F. & Lawler, J. V. Methicillin-resistant Staphylococcus aureus as a probable cause of antibiotic-associated enterocolitis. Case Rep. Infect. Dis. 2018, e3106305 (2018).

    Google Scholar 

89. Lichtman, J. S. et al. Host–microbiota interactions in the pathogenesis of antibiotic-associated diseases. Cell Rep. 14, 1049–1061 (2016).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

90. Pavia, A. T. et al. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella. J. Infect. Dis. 161, 255–260 (1990).

    CAS 
    PubMed 

    Google Scholar 

91. Holmberg, S. D., Osterholm, M. T., Senger, K. A. & Cohen, M. L. Drug-resistant Salmonella from animals fed antimicrobials. N. Engl. J. Med. 311, 617–622 (1984).

    CAS 
    PubMed 

    Google Scholar 

92. Gradel, K. O., Dethlefsen, C., Ejlertsen, T., Schønheyder, H. C. & Nielsen, H. Increased prescription rate of antibiotics prior to non-typhoid Salmonella infections: a one-year nested case–control study. Scand. J. Infect. Dis. 40, 635–641 (2008).

    PubMed 

    Google Scholar 

93. Doorduyn, Y., Van Den Brandhof, W. E., Van Duynhoven, Y. T. H. P., Wannet, W. J. B. & Van Pelt, W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol. Infect. 134, 617–626 (2006).

    CAS 
    PubMed 

    Google Scholar 

94. Malik, U. et al. Association between prior antibiotic therapy and subsequent risk of community-acquired infections: a systematic review. J. Antimicrob. Chemother. 73, 287–296 (2018).

    CAS 
    PubMed 

    Google Scholar 

95. Humphreys, H. et al. Four country healthcare associated infection prevalence survey 2006: risk factor analysis. J. Hosp. Infect. 69, 249–257 (2008).

    CAS 
    PubMed 

    Google Scholar 

96. Chen, Y. E., Fischbach, M. A. & Belkaid, Y. Skin microbiota–host interactions. Nature 553, 427–436 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

97. Nakatsuji, T. et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci. Transl. Med. 9, eaah4680 (2017).

    PubMed 
    PubMed Central 

    Google Scholar 

98. Zipperer, A. et al. Human commensals producing a novel antibiotic impair pathogen colonization. Nature 535, 511–516 (2016).

    CAS 
    PubMed 

    Google Scholar 

99. Belkaid, Y. & Segre, J. A. Dialogue between skin microbiota and immunity. Science 346, 954–959 (2014).

    CAS 
    PubMed 

    Google Scholar 

100. Liu, Q. et al. Staphylococcus epidermidis contributes to healthy maturation of the nasal microbiome by stimulating antimicrobial peptide production. Cell Host Microbe 27, 68–78.e5 (2020).

     CAS 
     PubMed 

     Google Scholar 

101. Man, W. H., de Steenhuijsen Piters, W. A. A. & Bogaert, D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat. Rev. Microbiol. 15, 259–270 (2017).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

102. Clark, S. E. Commensal bacteria in the upper respiratory tract regulate susceptibility to infection. Curr. Opin. Immunol. 66, 42–49 (2020).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

103. Santagati, M., Scillato, M., Patanè, F., Aiello, C. & Stefani, S. Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol. Med. Microbiol. 65, 23–31 (2012).

     CAS 
     PubMed 

     Google Scholar 

104. Horn, K. J. et al. Corynebacterium species inhibit Streptococcus pneumoniae colonization and infection of the mouse airway. Front. Microbiol. 12, 804935 (2021).

     PubMed 

     Google Scholar 

105. Thackray, L. B. et al. Oral antibiotic treatment of mice exacerbates the disease severity of multiple flavivirus infections. Cell Rep. 22, 3440–3453.e6 (2018).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

106. Margolis, D. J., Bowe, W. P., Hoffstad, O. & Berlin, J. A. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch. Dermatol. 141, 1132–1136 (2005).

     CAS 
     PubMed 

     Google Scholar 

107. Smith, H. S. et al. Antecedent antimicrobial use increases the risk of uncomplicated cystitis in young women. Clin. Infect. Dis. 25, 63–68 (1997).

     CAS 
     PubMed 

     Google Scholar 

108. Robinson, C. J. & Young, V. B. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 1, 279–284 (2010).

     PubMed 
     PubMed Central 

     Google Scholar 

109. Zacharioudakis, I. M., Zervou, F. N., Pliakos, E. E., Ziakas, P. D. & Mylonakis, E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am. J. Gastroenterol. 110, 381–390 (2015).

     PubMed 

     Google Scholar 

110. Stevens, E. J., Bates, K. A. & King, K. C. Host microbiota can facilitate pathogen infection. PLoS Pathog. 17, e1009514 (2021).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

111. Kluytmans-van den Bergh, M. F. Q. et al. Rectal carriage of extended-spectrum-β-lactamase-producing enterobacteriaceae in hospitalized patients: selective preenrichment increases yield of screening. J. Clin. Microbiol. 53, 2709–2712 (2015).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

112. Sheppard, S. K. Strain wars and the evolution of opportunistic pathogens. Curr. Opin. Microbiol. 67, 102138 (2022).

     CAS 
     PubMed 

     Google Scholar 

113. Donskey, C. J. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin. Infect. Dis. 39, 219–226 (2004).

     PubMed 

     Google Scholar 

114. Sim, C. K. et al. A mouse model of occult intestinal colonization demonstrating antibiotic-induced outgrowth of carbapenem-resistant Enterobacteriaceae. Microbiome 10, 43 (2022). Mice colonized with resistant bacteria at undetectable levels showed overgrowth following antibiotic treatment.

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

115. Maurice, C. F., Haiser, H. J. & Turnbaugh, P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152, 39–50 (2013).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

116. Bottery, M. J. et al. Inter-species interactions alter antibiotic efficacy in bacterial communities. ISME J. 16, 812–821 (2022).

     CAS 
     PubMed 

     Google Scholar 

117. Tavernier, S. et al. Community composition determines activity of antibiotics against multispecies biofilms. Antimicrob. Agents Chemother. 61, e00302–e00317 (2017).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

118. Brown, G. D. et al. Hidden killers: human fungal infections. Sci. Transl. Med. 4, 165rv13 (2012).

     PubMed 

     Google Scholar 

119. Mayer, F. L., Wilson, D. & Hube, B. Candida albicans pathogenicity mechanisms. Virulence 4, 119–128 (2013).

     PubMed 
     PubMed Central 

     Google Scholar 

120. Xu, J. et al. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J. Am. Board. Fam. Med. 21, 261–268 (2008).

     PubMed 

     Google Scholar 

121. MacDonald, T. M. et al. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q. J. Med. 86, 419–424 (1993).

     CAS 
     PubMed 

     Google Scholar 

122. Tan, C. T., Xu, X., Qiao, Y. & Wang, Y. A peptidoglycan storm caused by β-lactam antibiotic’s action on host microbiota drives Candida albicans infection. Nat. Commun. 12, 2560 (2021).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

123. Seelig, M. S. The role of antibiotics in the pathogenesis of Candida infections. Am. J. Med. 40, 887–917 (1966).

     CAS 
     PubMed 

     Google Scholar 

124. Takahashi, S. et al. Septic pulmonary embolism caused by Candida albicans after treatment for urinary multidrug-resistant Pseudomonas aeruginosa. J. Infect. Chemother. 14, 436–438 (2008).

     PubMed 

     Google Scholar 

125. Zhai, B. et al. High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nat. Med. 26, 59–64 (2020).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

126. Samonis, G. et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob. Agents Chemother. 37, 51–53 (1993).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

127. Spigaglia, P., Mastrantonio, P. & Barbanti, F. in Updates on Clostridium difficile in Europe: Advances in Microbiology, Infectious Diseases and Public Health Volume 8 (eds Mastrantonio, P. & Rupnik, M.) 137–159 (Springer International, 2018). https://doi.org/10.1007/978-3-319-72799-8_9.

128. Toth, M., Stewart, N. K., Smith, C. & Vakulenko, S. B. Intrinsic class D β-lactamases of Clostridium difficile. mBio 9, e01803–e01818 (2018).

     PubMed 
     PubMed Central 

     Google Scholar 

129. Eyre, D. W. et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N. Engl. J. Med. 369, 1195–1205 (2013). A study showing that many C. difficile infections are not the result of transmission chains in hospital settings.

     CAS 
     PubMed 

     Google Scholar 

130. Ayres, J. S., Trinidad, N. J. & Vance, R. E. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat. Med. 18, 799–806 (2012).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

131. Segura Munoz, R. R. et al. Experimental evaluation of ecological principles to understand and modulate the outcome of bacterial strain competition in gut microbiomes. ISME J. 16, 1594–1604 (2022).

     PubMed 
     PubMed Central 

     Google Scholar 

132. Hardin, G. The competitive exclusion principle. Science 131, 1292–1297 (1960).

     CAS 
     PubMed 

     Google Scholar 

133. Lentsch, V. et al. Combined oral vaccination with niche competition can generate sterilizing immunity against enteropathogenic bacteria. Preprint at bioRxiv https://doi.org/10.1101/2022.07.20.498444 (2022).

134. Lee, S. M. et al. Bacterial colonization factors control specificity and stability of the gut microbiota. Nature 501, 426–429 (2013).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

135. Murray, B. E., Rensimer, E. R. & Dupont, H. L. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim–sulfamethoxazole. N. Engl. J. Med. 306, 130–135 (1982).

     CAS 
     PubMed 

     Google Scholar 

136. Palleja, A. et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat. Microbiol. 3, 1255–1265 (2018).

     CAS 
     PubMed 

     Google Scholar 

137. Vollaard, E. J., Clasener, H. A. L., van Griethuysen, A. J. A., Janssen, A. J. & Sanders-Reijmers, A. J. Influence of amoxycillin, erythromycin and roxithromycin on colonization resistance and on appearance of secondary colonization in healthy volunteers. J. Antimicrob. Chemother. 20, 131–138 (1987).

     CAS 
     PubMed 

     Google Scholar 

138. Brandl, K. et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 455, 804–807 (2008).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

139. Ubeda, C. et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J. Clin. Invest. 120, 4332–4341 (2010). This study showed how VRE overgrow in the intestine during antibiotic treatment.

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

140. Soares, F. S. et al. Antibiotic-induced pathobiont dissemination accelerates mortality in severe experimental pancreatitis. Front. Immunol. 8, 1890 (2017).

     PubMed 
     PubMed Central 

     Google Scholar 

141. Drummond, R. A. et al. Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria. Cell Host Microbe 30, 1020–1033.e6 (2022).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

142. Knoop, K. A., McDonald, K. G., Kulkarni, D. H. & Newberry, R. D. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut 65, 1100–1109 (2016).

     CAS 
     PubMed 

     Google Scholar 

143. Forde, B. M. et al. Population dynamics of an Escherichia coli ST131 lineage during recurrent urinary tract infection. Nat. Commun. 10, 3643 (2019).

     PubMed 
     PubMed Central 

     Google Scholar 

144. Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269–284 (2015).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

145. Wheatley, R. M. et al. Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient. Nat. Commun. 13, 6523 (2022).

     PubMed 
     PubMed Central 

     Google Scholar 

146. Lawley, T. D. et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect. Immun. 77, 3661–3669 (2009).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

147. Magill, S. S. et al. Prevalence of antimicrobial use in US acute care hospitals, May–September 2011. J. Am. Med. Asssoc. 312, 1438–1446 (2014).

     CAS 

     Google Scholar 

148. Stracy, M. et al. Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections. Science 375, 889–894 (2022). Personalized antibiotic recommendations could reduce the emergence of resistance during antibiotic treatment.

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

149. Caballero, J. D. et al. Mixed strain pathogen populations accelerate the evolution of antibiotic resistance in patients. Nat. Commun. 14, 4083 (2023).

     Google Scholar 

150. Tchesnokova, V. L. et al. Pandemic uropathogenic fluoroquinolone-resistant Escherichia coli have enhanced ability to persist in the gut and cause bacteriuria in healthy women. Clin. Infect. Dis. 70, 937–939 (2020).

     PubMed 

     Google Scholar 

151. von Eiff, C., Becker, K., Machka, K., Stammer, H. & Peters, G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344, 11–16 (2001).

     Google Scholar 

152. Gasparrini, A. J. et al. Persistent metagenomic signatures of early-life hospitalization and antibiotic treatment in the infant gut microbiota and resistome. Nat. Microbiol. 4, 2285–2297 (2019).

     PubMed 
     PubMed Central 

     Google Scholar 

153. Korpela, K. et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat. Commun. 7, 10410 (2016).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

154. Jernberg, C., Löfmark, S., Edlund, C. & Jansson, J. K. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiol. Read. Engl. 156, 3216–3223 (2010).

     CAS 

     Google Scholar 

155. Wenzler, E., Mulugeta, S. G. & Danziger, L. H. The antimicrobial stewardship approach to combating Clostridium difficile. Antibiotics 4, 198–215 (2015).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

156. Baur, D. et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect. Dis. 17, 990–1001 (2017).

     PubMed 

     Google Scholar 

157. Aldeyab, M. A. et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J. Antimicrob. Chemother. 67, 2988–2996 (2012).

     CAS 
     PubMed 

     Google Scholar 

158. Wiesch, P. A., zur, Kouyos, R., Abel, S., Viechtbauer, W. & Bonhoeffer, S. Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLoS Pathog. 10, e1004225 (2014).

     Google Scholar 

159. Moser, C. et al. Antibiotic therapy as personalized medicine — general considerations and complicating factors. APMIS 127, 361–371 (2019).

     PubMed 

     Google Scholar 

160. Yeh, Y.-C., Huang, T.-H., Yang, S.-C., Chen, C.-C. & Fang, J.-Y. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front. Chem. 8, 286 (2020).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

161. Wang, Y. et al. Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles. J. Nanobiotechnol. 17, 103 (2019).

     Google Scholar 

162. Yao, J. et al. A pathogen-selective antibiotic minimizes disturbance to the microbiome. Antimicrob. Agents Chemother. 60, 4264–4273 (2016).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

163. Mu, H. et al. Pathogen-targeting glycovesicles as a therapy for salmonellosis. Nat. Commun. 10, 4039 (2019).

     PubMed 
     PubMed Central 

     Google Scholar 

164. Brochado, A. R. et al. Species-specific activity of antibacterial drug combinations. Nature 559, 259–263 (2018).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

165. Gutiérrez, B. & Domingo-Calap, P. Phage therapy in gastrointestinal diseases. Microorganisms 8, 1420 (2020).

     PubMed 
     PubMed Central 

     Google Scholar 

166. Cotter, P. D., Ross, R. P. & Hill, C. Bacteriocins — a viable alternative to antibiotics? Nat. Rev. Microbiol. 11, 95–105 (2013).

     CAS 
     PubMed 

     Google Scholar 

167. Meade, E., Slattery, M. A. & Garvey, M. Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: resistance is futile? Antibiotics 9, 32 (2020).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

168. Hatfull, G. F., Dedrick, R. M. & Schooley, R. T. Phage therapy for antibiotic-resistant bacterial infections. Annu. Rev. Med. 73, 197–211 (2022).

     PubMed 

     Google Scholar 

169. Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

170. Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954-17 (2017).

     PubMed 
     PubMed Central 

     Google Scholar 

171. Rea, M. C. et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc. Natl Acad. Sci. USA 107, 9352–9357 (2010).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

172. McDonald, L. C. et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 66, 987–994 (2018).

     CAS 
     PubMed 

     Google Scholar 

173. Yelin, I. et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat. Med. 25, 1728–1732 (2019).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

174. Suez, J. et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174, 1406–1423.e16 (2018).

     CAS 
     PubMed 

     Google Scholar 

175. Imperial, I. C. V. J. & Ibana, J. A. Addressing the antibiotic resistance problem with probiotics: reducing the risk of its double-edged sword effect. Front. Microbiol. 7, 1983 (2016).

     PubMed 
     PubMed Central 

     Google Scholar 

176. Kassam, Z., Lee, C. H., Yuan, Y. & Hunt, R. H. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am. J. Gastroenterol. 108, 500 (2013).

     PubMed 

     Google Scholar 

177. Pamer, E. G. Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns. Mucosal Immunol. 7, 210–214 (2014).

     CAS 
     PubMed 

     Google Scholar 

178. Taur, Y. et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci. Transl. Med. 10, eaap9489 (2018).

     PubMed 
     PubMed Central 

     Google Scholar 

179. DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019).

     PubMed 

     Google Scholar 

180. Amrane, S. & Lagier, J.-C. Fecal microbiota transplantation for antibiotic resistant bacteria decolonization. Hum. Microbiome J. 16, 100071 (2020). A comprehensive overview of the application of FMT to decolonize the gut of antibiotic resistance bacteria.

     Google Scholar 

181. Walker, A. W. et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 5, 220–230 (2011).

     CAS 
     PubMed 

     Google Scholar 

182. Stecher, B. & Hardt, W.-D. Mechanisms controlling pathogen colonization of the gut. Curr. Opin. Microbiol. 14, 82–91 (2011).

     CAS 
     PubMed 

     Google Scholar 

183. Pickard, J. M. & Núñez, G. Pathogen colonization resistance in the gut and its manipulation for improved health. Am. J. Pathol. 189, 1300–1310 (2019).

     PubMed 
     PubMed Central 

     Google Scholar 

184. Russell, A. B., Peterson, S. B. & Mougous, J. D. Type VI secretion system effectors: poisons with a purpose. Nat. Rev. Microbiol. 12, 137–148 (2014).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

185. Brunet, Y. R., Espinosa, L., Harchouni, S., Mignot, T. & Cascales, E. Imaging type VI secretion-mediated bacterial killing. Cell Rep. 3, 36–41 (2013).

     CAS 
     PubMed 

     Google Scholar 

186. Cotter, P. D., Hill, C. & Ross, R. P. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3, 777–788 (2005).

     CAS 
     PubMed 

     Google Scholar 

187. Vital, M., Rud, T., Rath, S., Pieper, D. H. & Schlüter, D. Diversity of bacteria exhibiting bile acid-inducible 7α-dehydroxylation genes in the human gut. Comput. Struct. Biotechnol. J. 17, 1016–1019 (2019).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

188. Didelot, X., Walker, A. S., Peto, T. E., Crook, D. W. & Wilson, D. J. Within-host evolution of bacterial pathogens. Nat. Rev. Microbiol. 14, 150–162 (2016).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

189. Ikuta, K. S. et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 400, 2221–2248 (2022).

     Google Scholar 

190. Magruder, M. et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat. Commun. 10, 5521 (2019).

     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

Download references